Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ACAD's Cash to Debt is ranked higher than
98% of the 830 Companies
in the Global Biotechnology industry.

( Industry Median: 56.40 vs. ACAD: No Debt )
Ranked among companies with meaningful Cash to Debt only.
ACAD' s 10-Year Cash to Debt Range
Min: 5.56   Max: 98090
Current: No Debt

5.56
98090
Equity to Asset 0.94
ACAD's Equity to Asset is ranked higher than
92% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. ACAD: 0.94 )
Ranked among companies with meaningful Equity to Asset only.
ACAD' s 10-Year Equity to Asset Range
Min: -2.13   Max: 0.98
Current: 0.94

-2.13
0.98
Interest Coverage No Debt
ACAD's Interest Coverage is ranked higher than
96% of the 382 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. ACAD: No Debt )
Ranked among companies with meaningful Interest Coverage only.
ACAD' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 3
Z-Score: 142.03
M-Score: -5.26
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -121918.95
ACAD's Operating margin (%) is ranked lower than
99% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. ACAD: -121918.95 )
Ranked among companies with meaningful Operating margin (%) only.
ACAD' s 10-Year Operating margin (%) Range
Min: -77691.67   Max: 35.82
Current: -121918.95

-77691.67
35.82
Net-margin (%) -121075.79
ACAD's Net-margin (%) is ranked lower than
99% of the 649 Companies
in the Global Biotechnology industry.

( Industry Median: -71.50 vs. ACAD: -121075.79 )
Ranked among companies with meaningful Net-margin (%) only.
ACAD' s 10-Year Net-margin (%) Range
Min: -77062.5   Max: 35.93
Current: -121075.79

-77062.5
35.93
ROE (%) -35.05
ACAD's ROE (%) is ranked lower than
56% of the 754 Companies
in the Global Biotechnology industry.

( Industry Median: -27.51 vs. ACAD: -35.05 )
Ranked among companies with meaningful ROE (%) only.
ACAD' s 10-Year ROE (%) Range
Min: -138.68   Max: 72.43
Current: -35.05

-138.68
72.43
ROA (%) -33.79
ACAD's ROA (%) is ranked lower than
60% of the 832 Companies
in the Global Biotechnology industry.

( Industry Median: -23.16 vs. ACAD: -33.79 )
Ranked among companies with meaningful ROA (%) only.
ACAD' s 10-Year ROA (%) Range
Min: -78.95   Max: 34.38
Current: -33.79

-78.95
34.38
ROC (Joel Greenblatt) (%) -14841.49
ACAD's ROC (Joel Greenblatt) (%) is ranked lower than
90% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: -344.23 vs. ACAD: -14841.49 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ACAD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -21643.52   Max: 2028.76
Current: -14841.49

-21643.52
2028.76
Revenue Growth (3Y)(%) -100.00
ACAD's Revenue Growth (3Y)(%) is ranked lower than
91% of the 396 Companies
in the Global Biotechnology industry.

( Industry Median: 0.30 vs. ACAD: -100.00 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ACAD' s 10-Year Revenue Growth (3Y)(%) Range
Min: -100   Max: 73.1
Current: -100

-100
73.1
EBITDA Growth (3Y)(%) 30.70
ACAD's EBITDA Growth (3Y)(%) is ranked higher than
83% of the 423 Companies
in the Global Biotechnology industry.

( Industry Median: -4.70 vs. ACAD: 30.70 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
ACAD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -42.6   Max: 30.7
Current: 30.7

-42.6
30.7
EPS Growth (3Y)(%) 29.20
ACAD's EPS Growth (3Y)(%) is ranked higher than
84% of the 408 Companies
in the Global Biotechnology industry.

( Industry Median: -7.70 vs. ACAD: 29.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
ACAD' s 10-Year EPS Growth (3Y)(%) Range
Min: -55.3   Max: 111.5
Current: 29.2

-55.3
111.5
» ACAD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

ACAD Guru Trades in Q2 2014

Andreas Halvorsen 4,757,878 sh (+32.22%)
Steven Cohen 1,082,000 sh (unchged)
Ron Baron 437,000 sh (-11.26%)
» More
Q3 2014

ACAD Guru Trades in Q3 2014

Paul Tudor Jones 10,748 sh (New)
Ron Baron 502,100 sh (+14.90%)
Andreas Halvorsen 4,324,890 sh (-9.10%)
Steven Cohen 925,000 sh (-14.51%)
» More
Q4 2014

ACAD Guru Trades in Q4 2014

Steven Cohen 1,018,600 sh (+10.12%)
Andreas Halvorsen 2,956,266 sh (unchged)
Paul Tudor Jones Sold Out
Ron Baron 497,530 sh (-0.91%)
Andreas Halvorsen 2,956,266 sh (-31.65%)
» More
Q1 2015

ACAD Guru Trades in Q1 2015

Louis Moore Bacon 80,000 sh (New)
Steven Cohen 2,247,300 sh (+120.63%)
Ron Baron 607,100 sh (+22.02%)
Andreas Halvorsen Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ACAD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 454.55
ACAD's Forward P/E is ranked lower than
102% of the 182 Companies
in the Global Biotechnology industry.

( Industry Median: 22.17 vs. ACAD: 454.55 )
Ranked among companies with meaningful Forward P/E only.
N/A
P/B 14.20
ACAD's P/B is ranked lower than
129% of the 713 Companies
in the Global Biotechnology industry.

( Industry Median: 3.32 vs. ACAD: 14.20 )
Ranked among companies with meaningful P/B only.
ACAD' s 10-Year P/B Range
Min: 0.48   Max: 16.77
Current: 14.2

0.48
16.77
P/S 42815.10
ACAD's P/S is ranked lower than
173% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: 7.28 vs. ACAD: 42815.10 )
Ranked among companies with meaningful P/S only.
ACAD' s 10-Year P/S Range
Min: 0   Max: 4055
Current: 42815.1

0
4055
Current Ratio 18.01
ACAD's Current Ratio is ranked higher than
88% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. ACAD: 18.01 )
Ranked among companies with meaningful Current Ratio only.
ACAD' s 10-Year Current Ratio Range
Min: 2.27   Max: 46.41
Current: 18.01

2.27
46.41
Quick Ratio 18.01
ACAD's Quick Ratio is ranked higher than
89% of the 805 Companies
in the Global Biotechnology industry.

( Industry Median: 4.07 vs. ACAD: 18.01 )
Ranked among companies with meaningful Quick Ratio only.
ACAD' s 10-Year Quick Ratio Range
Min: 2.27   Max: 46.41
Current: 18.01

2.27
46.41
Days Sales Outstanding 2.00
ACAD's Days Sales Outstanding is ranked higher than
97% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: 61.41 vs. ACAD: 2.00 )
Ranked among companies with meaningful Days Sales Outstanding only.
ACAD' s 10-Year Days Sales Outstanding Range
Min: 239.08   Max: 2932.17
Current: 2

239.08
2932.17

Valuation & Return

vs
industry
vs
history
Price/Net Cash 14.30
ACAD's Price/Net Cash is ranked lower than
98% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 5.10 vs. ACAD: 14.30 )
Ranked among companies with meaningful Price/Net Cash only.
ACAD' s 10-Year Price/Net Cash Range
Min: 0.69   Max: 19.49
Current: 14.3

0.69
19.49
Price/Net Current Asset Value 14.30
ACAD's Price/Net Current Asset Value is ranked lower than
98% of the 510 Companies
in the Global Biotechnology industry.

( Industry Median: 5.00 vs. ACAD: 14.30 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ACAD' s 10-Year Price/Net Current Asset Value Range
Min: 0.66   Max: 18.17
Current: 14.3

0.66
18.17
Price/Tangible Book 14.10
ACAD's Price/Tangible Book is ranked lower than
125% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. ACAD: 14.10 )
Ranked among companies with meaningful Price/Tangible Book only.
ACAD' s 10-Year Price/Tangible Book Range
Min: 0.63   Max: 13.63
Current: 14.1

0.63
13.63
Price/DCF (Projected) 68.00
ACAD's Price/DCF (Projected) is ranked lower than
147% of the 151 Companies
in the Global Biotechnology industry.

( Industry Median: 2.40 vs. ACAD: 68.00 )
Ranked among companies with meaningful Price/DCF (Projected) only.
ACAD' s 10-Year Price/DCF (Projected) Range
Min: 15.58   Max: 55.24
Current: 68

15.58
55.24
Earnings Yield (Greenblatt) -3.10
ACAD's Earnings Yield (Greenblatt) is ranked higher than
58% of the 802 Companies
in the Global Biotechnology industry.

( Industry Median: -4.40 vs. ACAD: -3.10 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) only.
ACAD' s 10-Year Earnings Yield (Greenblatt) Range
Min: -3.1   Max: 51153
Current: -3.1

-3.1
51153

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:DR6.Germany,
ACADIA Pharmaceuticals Inc was incorporated in Vermont in 1993 as Receptor Technologies, Inc. The Company reincorporated in Delaware in 1997. It is a biopharmaceutical Company engaged in the development and commercialization of small molecule drugs for the treatment of central nervous system disorders. It has four product candidates in clinical development led by pimavanserin, which is in Phase III development as a potential first-in-class treatment for Parkinsons disease psychosis. Pimavanserin is a new chemical entity that the Company discovered and has advanced to Phase III development as a potential first-in-class treatment for Parkinsons disease psychosis. Parkinsons disease psychosis is a debilitating disorder that develops in up to 60 percent of patients with Parkinsons disease. The Company has completed a Phase II trial with pimavanserin as a co-therapy in schizophrenia and has established plans for a future Phase II feasibility study to explore the use of pimavanserin as a treatment for Alzheimers disease psychosis. In collaboration with Allergan, it has discovered and is developing small molecule product candidates for the treatment of chronic pain. Chronic pain is a common form of persistent pain that may be related to a number of medical conditions and is often resistant to treatment. Allergan has conducted several Phase II trials in this program and has reported preliminary results, including positive proof-of-concept in a human visceral pain trial and efficacy signals in two chronic pain trials in the areas of fibromyalgia and irritable bowel syndrome. The Company has discovered and, in collaboration with Allergan, is developing a small molecule product candidate for the treatment of glaucoma. Glaucoma is a chronic eye disease and is the second leading cause of blindness in the world. This program has reached Phase I development. ACADIA and R-SAT are company's registered trademarks. The Company faces competition from pharmaceutical and biotechnology companies, as well as numerous academic and research institutions and governmental agencies, both in the United States and abroad. It is subject to federal, state and local laws and regulations governing the use, storage, handling, and disposal of these materials and specified waste products.
» More Articles for ACAD

Headlines

Articles On GuruFocus.com
Acadia Has Tough Road Ahead With Nuplazid Success Mar 14 2015 
Analysts Remain Bullish on Acadia Pharma Despite Drug Approval Delay Mar 13 2015 
Weekly CFO Sells Highlight: KO, KKD, PIR, NPSP, ACAD Apr 16 2013 
comment on ACAD Mar 02 2013 
ACADIA Pharmaceuticals Reports Second Quarter 2009 Financial Results Aug 05 2009 
ACADIA Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 5, 2009 Jul 29 2009 
ACADIA Pharmaceuticals Inc. Reports Operating Results (10-Q) May 11 2009 

More From Other Websites
ACADIA Pharmaceuticals to Present at the Jefferies 2015 Healthcare Conference on June 2, 2015 May 26 2015
ACADIA Pharmaceuticals to Present at the Jefferies 2015 Healthcare Conference on June 2, 2015 May 26 2015
ACADIA PHARMACEUTICALS INC Financials May 20 2015
Viking Global Liked AIG, Google, Actavis, Illumina And Cheniere Energy Last Quarter May 18 2015
10-Q for ACADIA Pharmaceuticals, Inc. May 09 2015
ACADIA INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of... May 09 2015
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ACADIA... May 08 2015
UPCOMING DEADLINE: Levi & Korsinsky, LLP Reminds Shareholders of Acadia Pharmaceuticals Inc. of... May 08 2015
Acadia reports 1Q loss May 07 2015
Acadia reports 1Q loss May 07 2015
ACADIA Pharmaceuticals Inc Earnings Call scheduled for 5:00 pm ET today May 07 2015
ACADIA PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition,... May 07 2015
ACADIA Pharmaceuticals Reports First Quarter 2015 Financial Results May 07 2015
Q1 2015 ACADIA Pharmaceuticals Inc Earnings Release - After Market Close May 07 2015
SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses in Excess of $100,000 From... May 06 2015
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care Conference... May 06 2015
ACADIA Pharmaceuticals to Present at the Bank of America Merrill Lynch 2015 Health Care Conference... May 06 2015
DEADLINE ALERT: Rigrodsky & Long, P.A. Reminds Shareholders Of ACADIA Pharmaceuticals Inc. Of... May 04 2015
ACADIA Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2015 Apr 30 2015
ACADIA Pharmaceuticals to Announce First Quarter Financial Results on May 7, 2015 Apr 30 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK